




COURSE

# Regenerative Medicine of the Retina

FRIDAY APRIL 5, 2019

STARTING AT 12:00 UNTIL SATURDAY APRIL 6, 15:00



**ACCREDITATION:** CME accreditation points will be provided by the Dutch Ophthalmologic Society

## INTENDED AUDIENCE

Clinicians and researchers in  
Ophthalmology

## REGISTRATION FEE

Specialist, senior researcher	€ 315,-
Resident, junior researcher	€ 215,-
Dinner	€ 25,-

## VENUE

Leiden University Medical Center

The retina is at the forefront of development of regenerative therapies such as gene therapy and stem cell therapy. Recently, the first-ever FDA-approved gene therapy was admitted to the market, for *RPE65*-associated retinal degeneration.

The course aims to present and discuss state-of-the-art developments by national and international experts

- on the options and progress in regenerative treatment for the retina
- on the spectrum of developing therapies for retinal degeneration
- on both clinical application and research on gene therapy and stem cell therapy

Information, registration and call for abstracts:  
[www.boerhaavecontinuingmedicaleducation.com](http://www.boerhaavecontinuingmedicaleducation.com)

# Regenerative Medicine of the Retina

The retina, as highly specialized creator of sight, is vulnerable to a broad range of monogenic and multifactorial causes of degeneration. As a relatively closed compartment, the eye is on the one hand relatively isolated and immune-privileged from the rest of the body, yet at the same time well-accessible to surgical intervention and a broad range of clinical examinations of its structure and function.

Subjects will range from AAV-mediated gene therapy, antisense oligonucleotide and CRISPR/Cas treatment, to optogenetics and stem cell therapy. In addition, important aspects of translation to clinical application will be discussed.

CALL FOR ABSTRACTS for a poster and/or rapid fire oral presentation. Prizes will be awarded for the best poster and oral presentations.

We look forward to welcoming you to the beautiful city of Leiden, which is located very centrally, within less than 30 minutes travel distance from Schiphol Airport.

Organizing Committee: prof.dr. Camiel Boon, dr. Jan Wijnholds and prof.dr. Gré Luyten of Leiden University Medical Center, prof.dr. Arthur Bergen of Amsterdam University Medical Center, prof.dr. Carel Hoyng of Radboud University Medical Center

## PROGRAMME FRIDAY APRIL 5<sup>TH</sup>

### **Adverse immune effects during retinal gene therapy**

Dominik Fischer, University Hospital Tübingen, Tübingen, Germany

### **Splice modulation therapy using antisense oligonucleotides**

Rob Collin, Radboud University Medical Center, Nijmegen, The Netherlands

### **Retinal RPE transplantation and prospects for the clinic**

James Bainbridge, UCL Institute of Ophthalmology, London, UK

### **Defining clinical endpoints for gene therapy studies**

Mays Talib, Leiden University Medical Center, Leiden, The Netherlands

### **Retinal gene therapy vectors**

Stylianos Michalakis, Ludwig-Maximilians-Universität München, Munich, Germany

### **Rapid fire session**

### **Closing comments**

### **Poster session and drinks**

### **Dinner**

## PROGRAMME SATURDAY APRIL 6<sup>TH</sup>

### **How to avoid failure in regenerative treatment trials for age-related macular degeneration**

Carel Hoyng, Radboud University Medical Center, Nijmegen, The Netherlands

### **Transplantation of iPSC-derived retinal tissue**

Céline Koster, Amsterdam University Medical Centers, Amsterdam, The Netherlands

### **Retinal optogenetics gene therapy**

Deniz Dalkara, Sorbonne Université, INSERM, CNRS, Paris, France

### **Bench to bedside development of retinal gene augmentation therapy**

Alun Barnard, University of Oxford, Oxford, UK

### **Retinal organoids as a model for hereditary retinal diseases**

Philip Wagstaff, Amsterdam University Medical Centers, Amsterdam, The Netherlands

### **Gene editing therapy and prospects for the clinic**

Manuel Goncalves, Leiden University Medical Center, Leiden, The Netherlands

### **Challenges in retinitis pigmentosa *CRB1* gene therapy**

Jan Wijnholds, Leiden University Medical Center, Leiden, The Netherlands

### **Rapid fire session**

### **hiPSC vasculature and vessels on chip**

Valeria Orlova, Leiden University Medical Center, Leiden, The Netherlands

### **Practical management of gene therapy/regenerative treatment trials for retinal dystrophies**

Dyon Valkenburg, Radboud University Medical Center, Nijmegen, The Netherlands

### **Poster prize, Oral presentation prize, Closing comments**

For more information and registration:  
[www.boerhaavecontinuingmedicaleducation.com](http://www.boerhaavecontinuingmedicaleducation.com)

Your address details are obtained via Iqvia. When you don't wish to receive any announcements for the Boerhaave courses, you can send an email to: boerhaavenascholing@lumc.nl; please include your profession in this email. You can also forward any changes concerning your address to the same email address.